Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Anastasia Hoover"'
Autor:
Hertzel C. Gerstein, Shun-Fu Lee, Guillaume Paré, M. Angelyn Bethel, Helen M. Colhoun, Anastasia Hoover, Mark Lakshmanan, Yanzhu Lin, Valentino Pirro, Hui-Rong Qian, Giacomo Ruotolo, Lars Ryden, Jonathan M. Wilson, Kevin L. Duffin
OBJECTIVE The glucagon-like peptide-1 receptor agonist dulaglutide reduced MACE in the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial. This article expores the relationship of selected biomarkers to both dulagluti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2640ca757c8cf50993017da4bd7b9737
https://doi.org/10.2337/figshare.22120097
https://doi.org/10.2337/figshare.22120097
Autor:
VALENTINA PIRRO, GUILLAUME PARE, SHUN FU LEE, HELEN M. COLHOUN, YANZHU LIN, JONATHAN M. WILSON, HUI-RONG QIAN, ANASTASIA HOOVER, KEVIN L. DUFFIN, HERTZEL C. GERSTEIN
Publikováno v:
Diabetes. 71
Dulaglutide (DU) reduced the risk of CV outcomes compared with placebo (PL) in the REWIND trial (NCT01394952) , with a MACE-3 (major adverse CV events) hazard ratio of 0.88 over 5.4 years. Participants were ≥50 years of age with T2D, A1C ≤9.5%, B
Autor:
JONATHAN M. WILSON, GUILLAUME PARE, SHUN FU LEE, HELEN M. COLHOUN, HUI-RONG QIAN, VALENTINA PIRRO, ANASTASIA HOOVER, MARK LAKSHMANAN, GIACOMO RUOTOLO, KEVIN L. DUFFIN, HERTZEL C. GERSTEIN
Publikováno v:
Diabetes. 71
In the REWIND trial, dulaglutide (DU) reduced the risk of CV outcomes compared with placebo (PL) (Major Adverse Cardiovascular Event [MACE]-3 hazard ratio 0.88) . This post hoc analysis studied circulating protein biomarkers associated with CV events